ArticleBMC infectious diseases2024
New-generation tetracyclines for severe macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a retrospective analysis.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and influencing factors of tooth discoloration in children using doxycycline: a meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Histone acetylation-regulated FBXO11-dependent degradation of BLIMP-1 promotes lung injury.Translational pediatrics · 2026Article
- Qingxuan Zhike Granules Modulate Gut Dysbiosis and Enhance Intestinal Repair in MurineJournal of microbiology and biotechnology · 2026Article
- Correlation analysis of serum CHI3L1, HMGB1, and CD62E detection with the prognosis of Mycoplasma pneumoniae in children.Journal of medical biochemistry · 2026Article
- Study on the value and mechanism of miR-369-5p in childhood pneumonia.BMC immunology · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- Construction of a nomogram combining CT and serum markers for predicting macrolide resistance gene mutation status in pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Efficacy and short-term safety of intravenous omadacycline as second-line therapy for macrolide- unresponsive Mycoplasma pneumoniae pneumonia in children: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- The Expression Levels and Clinical Significance of CARDS TX, MyD88, and IL-8 of Children With Severe Mycoplasma pneumoniae Pneumonia.Mediators of inflammation · 2026Article
- Analysis of the interventional effects of ambroxol hydrochloride and ontelukast sodium combined with azithromycin on immune function and C-reactive protein serum expression in children with severe Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Vertical transmission of scrub typhus: a case report of congenital infection.Emerging microbes & infections · 2025Article
- A case report of severe Mycoplasma pneumoniae pneumonia complicated by plastic bronchitis and Kawasaki disease.BMC infectious diseases · 2025Article
- A machine learning-based predictive model for multilobar pulmonary consolidation induced by macrolide-resistantMicrobiology spectrum · 2025Article
- Review
- Article
- Epidemiological and clinical characteristics of hospitalized pediatric patients with Mycoplasma pneumoniae pneumonia before and after the COVID-19 pandemic in China: a retrospective multicenter study.BMC infectious diseases · 2025Article
- IncreasedFrontiers in cellular and infection microbiology · 2024Article
- ResistantCanadian family physician Medecin de famille canadienArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMacrolide-resistant Mycoplasma pneumoniae (MRMP) strains are increasingly prevalent, leading to a rise in severe Mycoplasma pneumoniae pneumonia incidence annually, which poses a significant threat to children's health. This study aimed to compare the effectiveness and safety of oral minocycline and doxycycline for the treatment of severe MRMP pneumonia in children.
methodsThis retrospective analysis included children treated for severe MRMP pneumonia at the Pediatric Department of Tongji Hospital, Shanghai, China, between September 2023 and January 2024 using minocycline and doxycycline. The patients were divided into four groups according to treatment: oral doxycycline alone (DOX group), oral minocycline alone (MIN group), oral doxycycline with intravenous glucocorticoids (DOXG group), and oral minocycline with intravenous glucocorticoids (MING group). Student's t-test, Mann-Whitney U test, and χ
resultsA total of 165 patients were included in this study: 84 received minocycline, and 81 received doxycycline. The DOX group had higher fever resolution rates within 24, 48, and 72 h compared to the MIN group (63.2% vs. 31.8%, 79.0% vs. 63.6%, and 100% vs. 90.9%, respectively; all p < 0.05). The DOXG group showed higher fever resolution rates within 24 and 48 h than the MING group (92.3% vs. 83.4%, 100% vs. 92.7%, all p > 0.05). There were no statistically significant differences in time to imaging improvement, cough improvement, and disappearance of wet rales between groups, regardless of glucocorticoid combination. The longer the duration of fever prior to tetracycline therapy, the greater the likelihood of hypoxemia (p = 0.039) and a greater than two-fold elevation in the D-dimer level (p = 0.004).Univariate binary logistic regression model analysis revealed that CRP and erythrocyte sedimentation rate at disease onset were associated with defervescence within 24 h after treatment with tetracyclines alone (p = 0.020, p = 0.027), with erythrocyte sedimentation rate also influencing defervescence within 48 h (p = 0.022).
conclusionDoxycycline treatment resulted in a higher rate of defervescence than minocycline. Prompt treatment reduced the probability of pleural effusion, hypoxemia, pulmonary atelectasis, and D-dimer levels > 2 times the reference value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.